Skip to main content
SRRK logo

Scholar Rock Holding Corporation (SRRK) Stock: Price, Forecast & Analyst Target

Scholar Rock Holding Corporation (SRRK) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $48.13 (-4.45%), as of the Nov 20, 2026 trading session; market cap $5.87B.

Educational signal · not a buy or sell recommendation · How to read this

$48.13 −$2.24 (-4.45%) Market Cap $5.87B

Scholar Rock Holding Corporation · SRRK · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13: Scholar Rock develops treatments that target protein growth factor signaling, anchored by a late-stage candidate for spinal muscular atrophy. Because the company currently generates no commercial revenue, the investment case rests entirely on whether its clinical trial data can secure regulatory approval and transition the pipeline into a marketed product.

Price as of Nov 20, 2026

Key Statistics

21 of 100

MoonshotScore v2 · Scholar Rock Holding (SRRK)

Weak
Business Quality Poor (8)
Financial Safety Okay (59)
Valuation Rich (35)
Growth Durability Shrinking (12)
Momentum Rising (69)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Bottom-tier quality, stalling growth and an expensive valuation. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Rich; Growth Durability: Shrinking; Momentum: Rising.

  • EPS beat 0 of the last 3 reports
  • Altman Z 4.80 · Piotroski F 3

Holding back: weak fundamentals, soft growth

Helping: positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for SRRK (58 recorded, newest six shown)
RecordedScoreBand
27Weak
21Weak
21Weak
21Weak
21Weak
21Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$48.13
Change on the day-4.45%
52-week range$37.54–$61.76
Market capitalisation$5.87B—
Price / earnings (trailing)-21.42
Shares traded on the day2.08M
Beta (volatility vs the S&P 500)0.79

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 20, 2026: low $28, high $58, latest $48. $58 $28 high $58 Oct 17, 2025 Nov 20, 2026 · $48 $28Oct 17, 2025$30Oct 31, 2025$37Nov 14, 2025$44Nov 28, 2025$47Dec 12, 2025$46Dec 26, 2025$42Jan 9, 2026$44Jan 23, 2026$48Feb 6, 2026$48Feb 20, 2026$45Mar 6, 2026$45Mar 20, 2026$50Apr 2, 2026$50Apr 17, 2026$46May 1, 2026$49May 15, 2026$49May 29, 2026$44Jun 12, 2026$55Jun 26, 2026$57Jul 10, 2026$48Jul 24, 2026$53Aug 7, 2026$57Aug 21, 2026$55Sep 4, 2026$47Sep 18, 2026$47Oct 2, 2026$40Oct 16, 2026$44Oct 30, 2026$43Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Scholar Rock Holding (SRRK): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Negative
Financial Safety Neutral
Valuation Weak
Growth Durability Negative
Momentum Moderate

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Unfavorable read
Englander-style lens (simulated) Izzy Englander Unfavorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 19, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 21, 2026, except a card that shows its own read date.

1 · What is it?

What is Scholar Rock Holding (SRRK), and what does it report?

Short answer · as of

Scholar Rock operates as a clinical-stage biopharmaceutical developer focused on serious diseases like spinal muscular atrophy and treatment-resistant cancers.

Although the standard industry classification groups it with broad healthcare providers, the business functions strictly as a research engine that consumes cash to advance experimental therapies through trials.

Its income statement measures the heavy cost of scientific development against a complete lack of commercial sales, with research and development expenses constituting the bulk of its operational drain.

2 · Latest results

What do the latest results show for Scholar Rock Holding (SRRK)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 3 reports.

The latest financial results show widening net losses as the company funds late-stage clinical evaluations for its lead spinal muscular atrophy candidate. Without product revenue to offset costs, operating deficits grow directly in proportion to the rising expenses of clinical trials and administrative overhead.

This reporting period reflects a pure consumption phase where development milestones dictate the velocity of cash burn.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

3 · Financial strengths and risks

What are the financial strengths and risks for Scholar Rock Holding (SRRK)?

Short answer

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

The balance sheet is structured around cash reserves, which must fund all clinical programs until a drug reaches the market or a new financing event occurs. Current liquidity holds a comfortable margin over the near-term cash burn rate, providing a temporary runway for continued research.

The primary risk lies in trial failure or regulatory delay, which would force the company to raise fresh capital under distressed conditions before securing a commercial revenue stream.

4 · What to check next?

What should you watch next at Scholar Rock Holding (SRRK)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $4.51M · EPS -3.20 · 12 analysts.

Market watchers are closely tracking upcoming financial disclosures for updates on the clinical timeline of the lead spinal muscular atrophy asset and the early-stage solid tumor program. Cash runway projections remain the most critical metric in upcoming filings, as any acceleration in research spending shortens the window before the company must secure additional funding.

Furthermore, observers monitor the ongoing partnership with Gilead Sciences for any milestone progress in their joint fibrotic disease pipeline.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No quarterly income statement is held for SRRK.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Scholar Rock Holding compare with its peers?

Short answer

Scholar Rock Holding's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Unlike commercial-stage biotechnology firms that balance research spending with drug sales, Scholar Rock is defined entirely by its unapproved pipeline. Its specific focus on inhibiting the activation of latent myostatin distinguishes its scientific approach from peers utilizing standard gene therapies or broad immunosuppressants.

The heavy concentration of institutional ownership suggests the market treats the stock as a binary bet on its unique protein growth factor signaling platform rather than a traditional fundamental investment.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Kiniksa Pharmaceuticals, Ltd. (KNSA) Named competitor$93.89 Nov 20, 2026$7.38B98 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$308.89 Nov 20, 2026$9.15B96 5-pillar Nov 18, 2026
Corcept Therapeutics Incorporated (CORT) Same industry, near in market value$63.62 Nov 20, 2026$6.96B91 5-pillar Nov 18, 2026
Protagonist Therapeutics, Inc. (PTGX) Same industry, near in market value$121.40 Nov 20, 2026$7.92B88 5-pillar Nov 18, 2026
Edgewise Therapeutics, Inc. (EWTX) Same industry, near in market value$39.91 Nov 20, 2026$4.37B84 5-pillar Nov 18, 2026
Caris Life Sciences, Inc. (CAI) Same industry, near in market value$17.58 Nov 20, 2026$5.04B83 5-pillar Nov 18, 2026
Ligand Pharmaceuticals Incorporated (LGND) Same industry, near in market value$286.85 Nov 20, 2026$5.74B71 5-pillar Nov 18, 2026
Oruka Therapeutics, Inc. (ORKA) Same industry, near in market value$95.81 Nov 20, 2026$6.50B67 5-pillar Nov 18, 2026
Erasca, Inc. (ERAS) Same industry, near in market value$13.61 Nov 20, 2026$4.78B67 5-pillar Nov 18, 2026
Veradermics, Incorporated (MANE) Same industry, near in market value$119.52 Nov 20, 2026$5.04B66 5-pillar Nov 18, 2026
Belite Bio, Inc. (BLTE) Same industry, near in market value$127.38 Nov 20, 2026$5.17B64 5-pillar Nov 18, 2026
Xenon Pharmaceuticals Inc. (XENE) Named competitor$37.04 Nov 20, 2026$3.64B56 5-pillar Nov 18, 2026
Scholar Rock Holding (SRRK) — this page$48.13$5.87B21

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$58.00 – $84.00
Consensus target
$71.30
Median target
$71.00
Revenue estimate
$4.51M
EPS estimate
$-3.20

Consensus record · Captured .

Measured against a quoted price of $48.13 (as of Nov 20, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 26, 2026

Transactions
35
Identified insiders
9
Purchases
6
Sales
13
Other transactions
16

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held SRRK in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported SRRK in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Scholar Rock Holding (SRRK)?

Read these with our analysis →

SRRK Healthcare Stock FAQ

The last 2 questions are answered from this page's own dated data, not from the research.

How does the Gilead Sciences partnership affect the pipeline?

The strategic collaboration focuses on developing targeted inhibitors for fibrotic diseases. This partnership allows the company to expand its therapeutic reach beyond core muscular and oncology programs without bearing the entire research burden alone, a crucial benefit for a pre-revenue biopharmaceutical firm.

Why are net losses growing despite successful clinical trial conclusions?

Advancing a therapeutic candidate through late-stage development and preparing for potential commercialization requires aggressive spending on research and administration. Because the company generates no product sales, these escalating trial costs flow directly to the bottom line as widening losses.

What provides the capital runway for the apitegromab regulatory review process?

The company maintains a substantial reserve of cash and short-term investments that comfortably exceeds its annualized operating cash drain. This liquidity buffer is designed to fund operations through the immediate clinical milestones without requiring imminent equity dilution.

Are corporate insiders accumulating shares as the lead therapy nears potential approval?

Recent filings show a pattern of net selling among corporate officers. Distinct insiders have disposed of shares over the trailing period, opting for liquidity rather than accumulating more equity as the clinical pipeline advances.

What is the SRRK stock price today?

The last price recorded for Scholar Rock Holding Corporation (SRRK), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the SRRK price target?

The analyst consensus price target for Scholar Rock Holding Corporation (SRRK), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 18 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 1. What is Scholar Rock Holding (SRRK), and what does it report?: Sector / industry (provider taxonomy); Business description; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Scholar Rock Holding (SRRK)?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Business description
  • 3. What are the financial strengths and risks for Scholar Rock Holding (SRRK)?: Cash, investments and debt; Cash and short-term investments over time (USD millions); Cash runway cross-check (ours); Operating cash flow by quarter (USD millions)
  • 4. What should you watch next at Scholar Rock Holding (SRRK)?: Next earnings report; Business description; Cash runway cross-check (ours); Recent SEC filings
  • 5. How does Scholar Rock Holding compare with its peers?: Business description; Institutional ownership (13F); Annual revenue and net result (USD millions); Sector / industry (provider taxonomy)
  • FAQ: How does the Gilead Sciences partnership affect the pipeline?: Business description; Annual revenue and net result (USD millions); Sector / industry (provider taxonomy)
  • FAQ: Why are net losses growing despite successful clinical trial conclusions?: Quarterly income statement (USD thousands); Annual revenue and net result (USD millions); Business description
  • FAQ: What provides the capital runway for the apitegromab regulatory review process?: Cash, investments and debt; Cash runway cross-check (ours); Operating cash flow by quarter (USD millions)
  • FAQ: Are corporate insiders accumulating shares as the lead therapy nears potential approval?: Insider transactions, last 180 days; Named officers; Most recent Schedule 13D
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold SRRK

Funds in our ETF coverage that list SRRK among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
iShares Neuroscience and Healthcare ETF (IBRN)4.06%